1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Conatus Accepts Defeat For Emricasan In NASH

 
• By Joseph Haas

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.

Silhouette of an exhausted sportsman at sunset with the horizon in the background - Image
Conatus' long struggle with emricasan is at an end

Conatus Pharmaceuticals Inc. hung in and talked up the potential of future results as long as it could but finally conceded on 24 June that its pan-caspase inhibitor emricasan had demonstrated a lack of efficacy in multiple patient types in non-alcoholic steatohepatitis (NASH). The San Diego firm said it will wrap up its obligations related to emricasan with partner Novartis AG and consider its strategic alternatives going forward.

The last gasp for emricasan – which Conatus hoped would offer therapeutic potential from early- to late-stage liver disease –...

More from Clinical Trials

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

More from R&D

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.